Фоновый узор

Jinarc 30 mg + 60 mg comprimidos

О препарате

Introduction

Prospect: information for the patient

Jinarc 15 mg tablets

Jinarc 30 mg tablets

Jinarc 45 mg tablets

Jinarc 60 mg tablets

Jinarc 90 mg tablets

Tolvaptan

This medicine is subject to additional monitoring, which will speed up the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section 4 includes information on how to report these adverse effects.

Read this prospect carefully before starting to take this medicine, because

it contains important information for you.

  • Keep this prospect, as you may need to read it again.
  • If you have any doubts, consult your doctor or pharmacist.
  • This medicine has been prescribed only for you, and you must not give it to other people
  • who may have the same symptoms as you, as it may harm them.
  • If you experience adverse effects, consult your doctor or pharmacist even if they are
  • adverse effects that do not appear in this prospect. See section 4.

1. What is Jinarc and how is it used

Jinarc is a medication used to treat a disease known as «autosomal dominant polycystic kidney disease» (ADPKD). This disease leads to the development of fluid-filled cysts in the kidneys, causing pressure on surrounding tissues and reducing kidney function, potentially leading to kidney failure. Jinarc is used to treat ADPKD in adults with chronic kidney disease (CKD) in stages 1 to 4 with signs of rapid disease progression.

The active ingredient of Jinarc is tolvaptan, which blocks the effect of vasopressin, a hormone involved in the formation of cysts in the kidneys of patients with ADPKD. By blocking the effect of vasopressin, Jinarc slows the development of kidney cysts in patients with ADPKD, reduces disease symptoms, and increases urine production.

2. What you need to know before starting Jinarc treatment

Do not take Jinarc:

  • If you are allergic to tolvaptan or any of the other components of this medication (listed in section 6) or if you are allergic to benzazepine or benzazepine derivatives (for example, benazepril, conivaptan, mesilato de fenoldopam, or mirtazapina).
  • If you have been told that you have high levels of liver enzymes in your blood and this prevents you from receiving treatment with tolvaptan.
  • If your kidneys do not function (no urine production)
  • If you have a condition associated with very low blood volume (e.g., severe dehydration or hemorrhage).
    • If you have a condition that increases the amount of sodium in your blood.
    • If you do not feel the sensation of thirst.
    • If you are pregnant (see "Pregnancy and breastfeeding").
    • If you are breastfeeding (see "Pregnancy and breastfeeding").

Warnings and precautions

Consult your doctor before starting to take Jinarc:

  • If you have liver disease.
  • If you cannot drink enough water (see "Drink a sufficient amount of water" below) or if you have to limit your liquid intake.
    • If you have difficulty urinating or prostatic hypertrophy (enlargement of the prostate).
    • If you have a blood sodium level that is too high or too low.
  • If you have had a past allergic reaction to benzazepine, tolvaptan, or other benzazepine derivatives (e.g., benazepril, conivaptan, mesilato de fenoldopam, or mirtazapina), or to any of the other components of this medication (listed in section 6).
    • If you have diabetes.
    • If you have been told that you have high levels of uric acid in your blood (which may have caused gout).
  • Inform your doctor immediately if you experience signs that may indicate liver problems, such as:
  • Nausea
  • Vomiting
  • Fever
  • Fatigue
  • Loss of appetite
  • Abdominal pain
  • Dark urine
  • Icterus (yellowing of the skin or eyes)
  • Pruritus (itching) of the skin
  • Symptoms of pseudogripal syndrome (muscle and joint pain with fever)

During treatment with Jinarc, your doctor will request monthly blood tests to monitor changes in your liver function.

Drink a sufficient amount of water

Jinarc causes water loss because it increases urine production. This water loss may lead to adverse effects such as dry mouth and thirst, or even more serious adverse effects such as kidney problems (see section 4). Therefore, it is essential that you have access to water and can ingest sufficient amounts of liquid when you feel thirsty. Before going to bed, you should drink one or two glasses of water even if you do not feel thirsty, and also drink water after urinating at night. You should be especially careful if you have a disease that reduces your ability to ingest adequate liquids or if you have a higher risk of dehydration, for example, if you have vomiting or diarrhea. Due to the increased urine production, it is also essential to have a bathroom nearby at all times.

Children and adolescents

Jinarc has not been studied in children and adolescents (under 18 years) and is therefore not recommended for use in this population.

Other medications and Jinarc

Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including over-the-counter medications.

Particularly, inform your doctor that you are taking:

  • Treatments containing ketoconazole for fungal infections (fungal infections), macrolide antibiotics such as clarithromycin, or diltiazem for hypertension and chest pain.
  • These medications may increase the effects of Jinarc.
  • Medications that increase the level of sodium in the blood or that contain large amounts of salt, such as tablets that dissolve in water and those used to treat indigestion. These may increase the effects of Jinarc.
  • Digoxin (a medication for treating irregular heart rhythm and heart failure), dabigatran (used as an anticoagulant), rosuvastatin or pitavastatin (used to reduce blood cholesterol levels), methotrexate (used to treat cancer and arthritis), ciprofloxacin (an antibiotic), sulfasalazine (for the treatment of irritable bowel disease or rheumatoid arthritis), or metformin (for the treatment of diabetes). Jinarc may increase the effect of these medications.
  • Phenytoin or carbamazepine (medications for treating epilepsy), rifampicin (a medication for treating tuberculosis), or St. John's Wort (a traditional herbal remedy for mild depression and anxiety). It is advisable to avoid the use of any of these medications in combination with Jinarc because they may reduce the effects of Jinarc.
  • Diuretics (used to increase urine production). When taken at the same time as Jinarc, these medications may increase the risk of adverse effects due to water loss.
  • Diuretics or other medications for treating hypertension. When taken at the same time as Jinarc, these medications may increase the risk of experiencing low blood pressure when standing up or getting up.
  • Desmopressin (used to increase blood clotting factors or to control urine production or urinary incontinence). Jinarc may reduce the effect of desmopressin.

It may not be a problem to take these medications at the same time as Jinarc. Your doctor will decide what is best for you.

Use of Jinarc with beverages and alcohol

Do not take orange juice while taking Jinarc.

Pregnancy and breastfeeding

Do nottake this medication if you are pregnant or breastfeeding.

Potentially fertile women should use reliable contraceptive methods while being treated with this medication.

If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before taking this medication.

Driving and operating machinery

Some people may feel dizzy, weak, or tired after taking Jinarc. If you experience these effects, do not drive or use tools or machines.

Jinarc contains lactose.

If your doctor has told you that you have a lactose intolerance, consult with them before taking this medication.

3. How to Take Jinarc

Only specialized doctors in the treatment of PQRAD can prescribe Jinarc. Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.

Dose

The daily dose of Jinarc should be divided into two doses, one higher than the other. The higher dose should be taken in the morning when waking up, at least 30 minutes before breakfast, while the lower dose should be taken 8 hours later.

The dose combinations are:

45 mg + 15 mg

60 mg + 30 mg

90 mg + 30 mg

Normally, your treatment will start with a dose of 45 mg in the morning and 15 mg 8 hours later. Your doctor may gradually increase your dose to a maximum combination of 90 mg in the morning and 30 mg 8 hours later. Your doctor will regularly check how you tolerate the prescribed dose to determine the best dose for you. Always take the highest tolerable dose combination prescribed by your doctor.

If you are taking other medications that may increase the effects of Jinarc, you may receive lower doses. In this case, your doctor may prescribe Jinarc tablets with 30 or 15 mg of tolvaptan, which you should take once a day in the morning.

Administration form

Swallow the tablets without chewing and with a glass of water.

The morning dose should be taken at least 30 minutes before breakfast. The second daily dose can be taken with or without food.

If you take more Jinarc than you should

In case you have taken more tablets than the prescribed dose,drink plenty of water and immediately contact your doctor or the nearest hospital.Remember to bring the medication package with you so it is clear what you have taken. If you take the higher dose too late, you may have to go to the bathroom more frequently at night.

If you forget to take Jinarc

If you forget to take your medication, take the dose as soon as you remember on the same day. If you have not taken the tablets for a day, take the normal dose the next day.Do not take a double dose to compensate for the missed individual doses.

If you interrupt the treatment with Jinarc

If you interrupt the treatment with Jinarc, the kidney cysts may grow as fast as before starting the treatment with this medication. Therefore, you should only stop taking Jinarc if you notice emergency medical attention required side effects (see section 4) or if your doctor tells you to.

If you have any doubts about the use of this medication, consult your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine may cause side effects, although not everyone will experience them.

Severe side effects:

If you experience any of the following side effects, you may need urgent medical attention. Stop taking Jinarc and contact a doctor immediately or go to the nearest hospital if:

  • You have difficulty urinating;
  • You experience facial, lip, or tongue swelling, itching, a generalised skin rash, or wheezing or difficulty breathing (symptoms of an allergic reaction).

Jinarc may cause your liver not to function properly.

Consult your doctor if you experience symptoms of nausea, vomiting, fever, fatigue, loss of appetite, abdominal pain, dark urine, jaundice (yellowing of the skin or eyes), skin itching, or joint and muscle pain with fever.

Other side effects:

Very common: may affect more than 1 in 10 people

  • Thirst (excessive need to drink water)
  • Headache
  • Dizziness
  • Diarrhea
  • Dry mouth
  • Increased need to urinate, urinate at night, or urinate more frequently
  • Fatigue

Common: may affect up to 1 in 10 people

  • Dehydration
  • Elevated sodium, uric acid, and blood sugar levels
  • Gout
  • Loss of appetite
  • Difficulty falling asleep
  • Palpitations
  • Difficulty breathing
  • Abdominal pain
  • Feeling full, bloated stomach, or stomach discomfort
  • Constipation
  • Heartburn
  • Abnormal liver function
  • Skin rash
  • Itching
  • Muscle spasms
  • General weakness
  • Elevated liver enzyme levels in the blood
  • Weight loss

Rare: may affect up to 1 in 100 people

  • Elevated bilirubin levels (a substance that can cause yellowing of the skin or eyes) in the blood

Unknown frequency: cannot be estimated from available data

  • Allergic reactions (see above)
  • Acute liver failure (ALF)

Reporting of side effects

If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information on the safety of this medicine.

5. Jinarc Storage

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the outer box, on the blister pack, and on the blister after the abbreviation «CAD». The expiration date is the last day of the month indicated.

Store in the original packaging to protect it from light and moisture.

Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.

6. Contents of the packaging and additional information

Composition of Jinarc

The active ingredient is tolvaptan.

Each Jinarc 15 mg tablet contains 15 mg of tolvaptan.

Each Jinarc 30 mg tablet contains 30 mg of tolvaptan.

Each Jinarc 45 mg tablet contains 45 mg of tolvaptan.

Each Jinarc 60 mg tablet contains 60 mg of tolvaptan.

Each Jinarc 90 mg tablet contains 90 mg of tolvaptan.

The other components are lactose monohydrate (see section 2), maize starch, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate and aluminium lake of indigo carmine.

Appearance of Jinarc and contents of the pack

The different doses of Jinarc tablets have different shapes and markings:

Jinarc 15 mg tablet: blue, triangular, marked with "OTSUKA" and "15" on one side.

Jinarc 30 mg tablet: blue, round, marked with "OTSUKA" and "30" on one side.

Jinarc 45 mg tablet: blue, square, marked with "OTSUKA" and "45" on one side.

Jinarc 60 mg tablet: blue, modified rectangular, marked with "OTSUKA" and "60" on one side.

Jinarc 90 mg tablet: blue, pentagonal, marked with "OTSUKA" and "90" on one side.

The medicinal product is supplied in the following pack sizes:

Jinarc 15 mg tablets: blisters with 7 or 28 tablets

Jinarc 30 mg tablets: blisters with 7 or 28 tablets

Jinarc 45 mg tablets + Jinarc 15 mg tablets: blisters with or without a carton with

14 (7 high-dose tablets + 7 low-dose tablets),

28 (14 high-dose tablets + 14 low-dose tablets) or

56 (28 high-dose tablets + 28 low-dose tablets) tablets.

Jinarc 60 mg tablets + Jinarc 30 mg tablets: blisters with or without a carton with 14 (7 high-dose tablets + 7 low-dose tablets),

28 (14 high-dose tablets + 14 low-dose tablets) or

56 (28 high-dose tablets + 28 low-dose tablets) tablets.

Jinarc 90 mg tablets + Jinarc 30 mg tablets: blisters with or without a carton with

14 (7 high-dose tablets + 7 low-dose tablets),

28 (14 high-dose tablets + 14 low-dose tablets) or

56 (28 high-dose tablets + 28 low-dose tablets) tablets.

Only some pack sizes may be marketed.

Marketing authorisation holder

Otsuka Pharmaceutical Netherlands B.V.

Herikerbergweg 292

1101 CT, Amsterdam

Netherlands

Manufacturer

AndersonBrecon (UK) Limited

Units 2-7, Wye Valley Business Park, Brecon Road, Hay-on-Wye

Hereford - HR3 5PG

UK

Almac Pharma Services Ltd.

Almac House, 20 Seagoe Industrial Estate

Craigavon - BT63 5QD

UK

Almac Pharma Service (Ireland) Limited

Finnabair Industrial Estate, Dundalk,

Co. Louth - A91 P9KD

Ireland

Millmount Healthcare Limited

Block-7, City North Business Campus, Stamullen, Co.

Meath, K32 YD60

Ireland

For further information about this medicinal product, please contact the local representative of the marketing authorisation holder:

België/Belgique/Belgien

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Lietuva

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

????????

Otsuka Pharmaceutical Netherlands B.V.

Te?: +31 (0) 20 85 46 555

Luxembourg/Luxemburg

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Ceská republika

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Magyarország

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Danmark

Otsuka Pharma Scandinavia AB

Tlf: +46854 528 660

Malta

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Deutschland

Otsuka Pharma GmbH

Tel: +49691 700 860

Nederland

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Eesti

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Norge

Otsuka Pharma Scandinavia AB

Tlf: +46854 528 660

Ελλ?δα

Otsuka Pharmaceutical Netherlands B.V.

Thλ:+31 (0) 20 85 46 555

Österreich

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

España

Otsuka Pharmaceutical S.A

Tel: +3493 2081 020

Polska

Otsuka Pharmaceutical Netherlands B.V.

Tel:+31 (0) 20 85 46 555

France

Otsuka Pharmaceutical France SAS

Tél: +33147 080 000

Portugal

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Hrvatska

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

România

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Ireland

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Slovenija

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Ísland

Otsuka Pharma Scandinavia AB

Sími: +46854 528660

Slovenská republika

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

Italia

Otsuka Pharmaceutical Italy S.r.l.

Tel: +39 02 00 63 27 10

Suomi/Finland

Otsuka Pharma Scandinavia AB

Puh/Tel: +46854 528 660

Κ?προς

Otsuka Pharmaceutical Netherlands B.V.

Thλ:+31 (0) 20 85 46 555

Sverige

Otsuka Pharma Scandinavia AB

Tel: +46854 528 660

Latvija

Otsuka Pharmaceutical Netherlands B.V.

Tel: +31 (0) 20 85 46 555

United Kingdom

Otsuka Pharmaceuticals (UK) Ltd.

Tel: +44 (0)203 747 5300

Date of last revision of this leaflet: MM/AAAA.

Other sources of information

Further detailed information on this medicinal product is available on the website of the European Medicines Agency:

http://www.ema.europa.eu/

Страна регистрации
Активное вещество
Требуется рецепт
Да
Производитель
Состав
Lactosa monohidrato (16.838 mg mg), Lactosa monohidrato (73.826 mg mg)
Информация носит справочный характер и не является медицинской рекомендацией. Перед приёмом любых препаратов проконсультируйтесь с врачом. Oladoctor не несёт ответственности за медицинские решения, принятые на основе этого контента.

Общайтесь с врачом онлайн

Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.

5.01 отзыв
Doctor

Anna Moret

Dermatology18 лет опыта

Dr. Anna Moret is a board-certified dermatologist and dermatovenereologist. She specialises in adult and pediatric dermatology, venereology, aesthetic skin care, and general medicine. Her consultations are evidence-based and tailored to each patient’s dermatological needs.

Dr. Moret provides expert evaluation and treatment for: • Skin conditions such as eczema, acne, rosacea, dermatitis, and psoriasis • Hair and scalp issues including hair loss, dandruff, and seborrheic dermatitis • Pediatric skin problems — from newborns to adolescents • Sexually transmitted infections (STIs) and dermatovenereology • Aesthetic concerns: skin ageing, non-invasive cosmetic treatments • Skin allergies and hypersensitivity reactions • Mole checks, lesion evaluation, and skin cancer screening • Skincare advice and personalised cosmeceutical routines

Combining dermatology with general medical knowledge, Dr. Moret offers comprehensive care that addresses both skin health and underlying conditions. She also holds certification from the Canadian Board of Aesthetic Medicine, ensuring an internationally aligned approach to aesthetic dermatology.

Записаться на онлайн-консультацию
5.01 отзыв
Doctor

Alina Tsurkan

Family Medicine12 лет опыта

Dr. Alina Tsurkan is a licensed family medicine doctor based in Portugal. She provides personalised primary care for both adults and children, helping patients manage a wide range of everyday health concerns with professionalism and attention to detail.

Dr. Tsurkan diagnoses and treats common conditions such as: • Respiratory infections (cold, flu, bronchitis, pneumonia) • Eye conditions: conjunctivitis (infectious and allergic) • ENT problems (sinusitis, ear infections, tonsillitis) • Digestive issues including gastritis, acid reflux, and IBS • Urinary tract infections and other frequent infections • Chronic conditions such as high blood pressure, diabetes, and thyroid disorders • Headaches and migraines

In addition to symptom-based care, Dr. Tsurkan focuses on prevention and early detection. She offers regular health check-ups, follow-up care, and medical prescriptions tailored to each patient’s needs.

With a comprehensive and caring approach, Dr. Tsurkan supports patients at every stage of life — from acute illnesses to long-term health management.

Записаться на онлайн-консультацию
5.09 отзывов
Doctor

Andrei Popov

General Medicine6 лет опыта

Dr. Andrei Popov is a licensed pain management specialist and general practitioner based in Spain. He provides expert online care for adults dealing with both chronic and acute pain, as well as a wide range of everyday health concerns.

He specialises in diagnosing and treating pain conditions that affect quality of life, including: • Chronic pain lasting more than 3 months • Migraines and recurring headaches • Neck, back, lower back, and joint pain • Post-traumatic pain following injury or surgery • Nerve-related pain, fibromyalgia, and neuralgia In addition to pain management, Dr. Popov helps patients with: • Respiratory infections (colds, bronchitis, pneumonia) • High blood pressure and metabolic conditions such as diabetes • Preventive care and routine health check-ups

Online consultations last up to 30 minutes and include a detailed symptom review, personalised treatment planning, and medical follow-up when needed.

Dr. Popov’s approach is rooted in evidence-based medicine, combined with individualised care tailored to each patient’s history, lifestyle, and clinical needs.

Записаться на онлайн-консультацию
5.01 отзыв
Doctor

Yevgen Yakovenko

General Surgery11 лет опыта

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain, with a diverse clinical background in general and pediatric surgery, internal medicine, and pain management. With a strong focus on both practice and research, he provides comprehensive medical consultations for adults and children, covering both surgical and therapeutic needs.

Dr. Yakovenko offers expert care in the following areas: • Diagnosis and treatment of acute and chronic pain • Pre- and postoperative care, including risk assessment and follow-up • Surgical conditions such as hernias, gallbladder disease, and appendicitis • Pediatric surgery consultations, including congenital conditions and minor procedures • Trauma care: fractures, soft tissue injuries, and wound management • Oncological surgery consultation and post-treatment care • Cardiovascular and respiratory conditions (internal medicine) • Orthopedic concerns and post-trauma rehabilitation • Radiological interpretation for surgical planning

In addition to his clinical work, Dr. Yakovenko actively participates in medical research and international collaboration. He is a member of the German Surgeons Association (BDC), affiliated with the General Practitioners Association of Las Palmas, and works with the German Consulate in the Canary Islands. He regularly attends international medical conferences and has authored scientific publications.

With over a decade of multidisciplinary experience, Dr. Yakovenko delivers precise, evidence-based care tailored to each patient’s needs.

Записаться на онлайн-консультацию
Смотреть всех врачей

Следите за новостями и экономьте на услугах

Советы врачей, обновления платформы и скидки для подписчиков.

Следите за нами в соцсетях
УслугиВрачиПомощь
Поиск